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A limitation of our study was that 
only 5 patients had documented se-
roconversion for CHIKV. However, 
high titers were found in all but 1 pa-
tient (>1,280 in 21 patients and 640 in 
2 patients). This patient, who had a ti-
ter of 80, was an Italian who had prob-
ably not been previously exposed to 
CHIKV. Thus, the risk for misclassi-
ﬁ  cation was low. PCR for early detec-
tion of infection was not used because 
only 3 persons were tested within 10 
days of symptom onset. Two of these 
persons, who were tested 7 days after 
symptom onset, already had antibod-
ies to CHIKV.
In conclusion, a high proportion 
of travelers with symptoms of CHIKV 
infection who returned from areas with 
outbreaks of this infection or where this 
virus was endemic were seropositive. A 
lower proportion of patients had anti-
bodies to DENV. CHIKV-positive pa-
tients were more likely to have a rash 
than those negative for both CHIKV 
and DENV. As suggested by previous 
studies (9), a rash was more common 
among CHIKV-positive patients than 
in DENV-infected patients, but the dif-
ference was not signiﬁ  cant. Our study 
suggests that identiﬁ  cation of predictors 
of infection with CHIKV is feasible, al-
though it is complicated by cocircula-
tion of DENV in the same areas.
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Acinetobacter spp. 
in Gunshot Injuries
To the Editor: Challenges posed 
by  Acinetobacter spp. result from 
multidrug resistance, nosocomial 
spread, and hospital-wide outbreaks 
(1–3). We evaluated Acinetobacter 
spp. infections from gunshot injuries 
received during the April 2006 East 
Timor conﬂ   ict (for a description of 
these events and further reading, see 
http://en.wikipedia.org/wiki/2006_
East_Timorese_crisis). 
We reviewed records of 15 injured 
East Timorese police ofﬁ  cers. Median 
age was 29 years (range 25–45 years); 
13 were male. Typical injuries were 
from multiple high-velocity gunshots 
and shrapnel. All patients had under-
gone surgery for stabilization and 
wound debridement before evacuation 
to the Royal Darwin Hospital (RDH) 
in Australia; most had likely received 
antimicrobial drugs including ampi-
cillin, gentamicin, metronidazole, and 
ceftriaxone. They arrived at RDH a 
median of 3 days after injury (range 
2–12 days).
The patients were separated from 
other hospital inpatients on arrival; 
they were managed as a cohort, they 
had dedicated nursing staff, and bar-
rier contact precautions were prac-
ticed. However, the patients were not 
routinely screened for colonization 
with microbiologic organisms. Addi-
tional surgical management, includ-
ing further wound debridement, was 
performed on 12 of the 15 patients (11 
within 48 hours of arrival at RDH); 
intraoperative samples of bone, soft 
tissue, and wounds were submitted for 
culture.
From 13 patients (including all 
11 with gunshot wounds), 19 Acineto-
bacter spp. isolates were recovered. 
Acinetobacter spp. was cultured from 
deep wound tissue obtained during sur-
gery from 9 patients. Substantial anti-
microbial drug resistance was demon-
strated by automated testing (Vitek 2, 
bioMérieux, Marcy l’Etoile, France) 
(Table). All 19 Acinetobacter spp. iso-
lates were classiﬁ  ed as multidrug resis-
tant (resistant to >3 drug classes) (4). 
Isolates from 10 of the 13 culture-pos-
itive patients (12 of 19 isolates) were 
resistant to all tested drugs except me-
ropenem and amikacin. Susceptibility 
testing for tigecycline and tetracycline 
was not performed. No isolate was 
metallo-β-lactamase positive by phe-
notypic analysis according to tablet 
disk diffusion method using imipenem 
and imipenem plus EDTA Neo-Sen-
sitabs (Rosco Diagnostica, Taastrup, 
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spp. (15 isolates) far exceeded that of 
other organisms: Stenotrophomonas (5 
isolates); Pseudomonas aeruginosa (3 
isolates); Staphylococcus aureus and 
Enterococcus spp. (2 isolates each); 
and Pseudomonas putida, Enterobac-
ter cloacae,  Staphylococcus hemo-
lyticus, and Mycoplasma hominis (1 
isolate each).
On the basis of clinical assessment 
by the treating surgeon and infectious 
diseases physician, 11 patients were 
treated for Acinetobacter spp. infec-
tion. Patients 1–5 had comminuted 
compound fractures associated with 
intraoperative deep wound tissue that 
was culture positive for Acinetobacter 
spp. and were treated for osteomy-
elitis; patients 6–11 were treated for 
wound infections; patients 6–8 had 
intraoperative deep wound tissue cul-
ture positive for Acinetobacter spp.; 
patients 9–10 had superﬁ  cial wound 
swabs that were culture positive; and 
patient 11 had a positive culture from 
a nonsurgical site. Of these 11 pa-
tients, 4 had fever >38°C on the day of 
admission to RDH (2 of whom had a 
leukocyte count >20,000/μL), and an-
other 2 had visible pus, necrotic tissue, 
or both. The surgical approach to these 
patients involved delayed wound clo-
sure; fracture ﬁ  xation; vacuum dress-
ings; and skin, bone, and nerve grafts. 
Choice and duration of antimicrobial 
drug therapy was guided by suscepti-
bility testing and experience (4). Pre-
sumed osteomyelitis caused by multi-
drug-resistant (MDR) Acinetobacter 
spp. was treated with meropenem in 
combination with amikacin for at least 
2 weeks, followed by another 2 weeks 
of meropenem monotherapy. Wound 
infections were similarly treated with 
combination therapy initially, but ami-
kacin was stopped earlier. No ami-
noglycoside toxicity was observed. 
Treatment was stopped at 4 weeks 
if no signs of infection were present 
(healed wound plus apyrexia and a 
C-reactive protein level <20 mg/L). 
Patient 12 was colonized with MDR 
Acinetobacter spp. and was treated for 
aspiration pneumonia; patient 13 had 
MDR Acinetobacter spp. colonization 
of a central venous catheter.
Follow-up after completion of 
therapy ranged from 4 to 23 weeks. 
No patients had recurrence of infec-
tion or isolation of Acinetobacter spp. 
Deﬁ   ning osteomyelitis and wound 
infection caused by Acinetobacter 
spp. was problematic for clinicians 
(4–6), and some assumed infections 
may have represented colonization. 
Because treatment for MDR Aci-
netobacter spp. in this setting can be 
protracted and toxic (e.g., from ami-
noglycosides), our review highlights 
the potential beneﬁ  ts of applying pro-
spectively documented criteria such as 
abnormal bone histologic ﬁ  ndings for 
osteomyelitis and a workable deﬁ  ni-
tion of deep tissue infection to better 
guide treatment decisions.
RDH had not experienced out-
breaks of healthcare-associated infec-
tion or colonization with MDR Aci-
netobacter spp. before or after (as of 
January 1, 2007) the 2006 East Timor 
conﬂ   ict, except for positive isolates 
from 5 patients evacuated from the 
Bali bombings of 2002 and 2005. Be-
cause all but 1 isolate were recovered 
within 48 hours of admission, primary 
inoculation of Acinetobacter spp. into 
wounds is assumed to have occurred 
either at the time of injury (from envi-
ronmental sources or preexisting skin 
colonization), from nosocomial trans-
mission in East Timor (before trans-
fer to RDH), or during evacuation 
to RDH. Environmental and patient-
based screening at sites of primary 
care may help resolve the uncertainty 
of which source is most likely.
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Table. Susceptibility of Acinetobacter spp. isolates to antimicrobial drugs, % (n = 19)* 
Drug Susceptible Intermediate Resistant
Amikacin 100 0 0
Ampicillin 0 0 100
Ceftazidime 21 26 53
Ceftriaxone 0 0 100
Ciprofloxacin 26 16 58
Gentamicin 21 0 79
Meropenem 100 0 0
Piperacillin/tazobactam 26 32 42
Ticarcillin/clavulanic acid 21 21 58
Tobramycin 21 16 63
Trimethoprim/sulfamethoxazole 11 0 89
*Isolates from gunshot wounds of 15 persons injured in East Timor, 2006. 
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Case Cluster of 
Necrotizing 
Fasciitis and 
Cellulitis 
Associated with 
Vein Sclerotherapy
To the Editor: Varicose vein 
sclerotherapy is a commonly per-
formed cosmetic surgical procedure 
in which a sclerosing agent is injected 
into small varicose veins of the leg 
by using small gauge needles. It is 
regarded as a minor, safe procedure, 
usually performed in an ofﬁ  ce clinic 
(1). We describe a cluster of infections 
with group A Streptococcus spp. as-
sociated with throat carriage in a cos-
metic surgeon.
In early December 2006, 3 pa-
tients were seen over a 10-day period 
at Geelong Hospital with infections 
following varicose vein sclerotherapy. 
All patients had undergone varicose 
vein sclerotherapy with polidocanol 
(Laurath-9; Aethoxysklerol, BSN 
Medical, Mount Waverley, Victoria, 
Australia) at a clinic of a single cos-
metic surgeon. The index patient (pa-
tient A) had toxic shock syndrome and 
necrotizing fasciitis of the treated legs. 
The 2 other patients (patients C and D) 
had multifocal cellulitis directly corre-
lating to the injection sites. The time 
between sclerotherapy and disease on-
set was 1–2 days.
A case-patient was deﬁ  ned as a 
patient who had undergone sclerother-
apy at the clinic and subsequently had 
infection directly related to the site 
of sclerosant injection. Events were 
dated from the day on which the index 
patient had her surgical procedure. We 
reviewed clinic notes and infection 
control procedures in conjunction with 
the Department of Human Services 
of the State Government of Victoria, 
Australia. Specimens, where avail-
able, were collected for culture from 
patients by the treating clinicians. A 
throat swab was taken from the cos-
metic surgeon. Specimens were trans-
ported and cultured by using standard 
methods.
During the outbreak period, 44 pa-
tients had vein sclerotherapy with 3% 
polidocanol at the cosmetic surgeon’s 
clinic. In addition to the 3 patients 
identiﬁ  ed on admission to hospital, a 
fourth patient (patient B) sought treat-
ment from her general practitioner 
for medical care for a postprocedure 
infection. All patients had procedures 
on day 1 or day 7 (Figure); patients A 
and B were seen consecutively on day 
1, and 2 patients were treated between 
patients C and D on day 7.
Patient A required surgical de-
bridement, intravenous antimicrobial 
drugs, intensive care, and hyperbaric 
oxygen therapy. Intraoperative speci-
mens taken from her during debride-
ment cultured group A Streptococcus 
spp. Patients B, C, and D had cellu-
litis, but no specimens suitable for 
microbiologic diagnosis of cellulitis 
were taken for culture. Patient B was 
treated with oral antimicrobial agents 
as an outpatient. Patient C was admit-
ted to hospital for intravenous antimi-
crobial therapy, and patient D showed 
no improvement on oral antimicrobial 
therapy as an outpatient and was sub-
sequently admitted to hospital for in-
travenous antimicrobial agents.
Group A Streptococcus spp. was 
isolated from a throat swab taken on 
day 16 from the cosmetic surgeon. 
He reported no upper respiratory tract 
infection symptoms before the out-
break. He also reported that antisep-
tic skin preparation was not routinely 
used during the procedures; nor were 
gloves used. However, alcohol hand 
rubs were used between patients. The 
surgeon had not changed his infection 
control procedures recently and had 
not been aware of any infective com-
plications previously. Environmental 
surface swabs taken on day 14 from 
3 different areas (procedural trolley, 
surgical spotlight, and examination 
couch) in the clinic during the assess-
ment yielded no pathogenic organisms. 
The infection control assessment team 
noted overall cleaning, disinfection, 
and hand hygiene to be inadequate. 
Decolonization of the surgeon 
was performed by using rifampin 
600 mg daily and amoxicillin 500 
Figure. Days of procedures for infected and noninfected patients and their ﬁ  rst manifestations 
of infection. , uninfected; , infected; Δ, patients A and B seen with infection; Ο, patient C 
seen with infection; and ×, patient D seen with infection.
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